Skip to content

Clinical Study on the Efficacy Evaluation of Peiyuan Huayu Formula in Treating Chronic Subdural Hematoma

Clinical Study on the Efficacy Evaluation of Peiyuan Huayu Formula in Treating Chronic Subdural Hematoma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072255
Enrollment
Unknown
Registered
2023-06-07
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Subdural Hematoma

Interventions

control group:Using conventional therapy instead of traditional Chinese medicine treatment
Treatment group:Using conventional treatment methods and traditional Chinese medicine Peiyuan Huayu Formula for treatment

Sponsors

Affiliated Hospital of Shaanxi University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The subjects voluntarily joined this study and signed an informed consent form; 2. Age = 18 years old and = 85 years old, regardless of gender; 3. Confirmed as chronic subdural hematoma through cranial CT or MRI examination.

Exclusion criteria

Exclusion criteria: 1. Received treatment with traditional Chinese medicine or statins for promoting blood circulation and resolving stasis within two weeks before enrollment; 2. Allergy to the drugs used in this study; 3. Being treated with anticoagulant, antiplatelet, and thrombolytic drugs; 4. Individuals with severe diseases such as hematopoietic system, liver, kidney, heart, and coagulation function: 5. Have a history of spontaneous cerebral hemorrhage, traumatic cerebral hemorrhage, and other intracranial hemorrhage diseases; 6. The subject is unable to cooperate with the examination or follow-up (unable to cooperate with the physical examination and complete relevant examinations Check, including rating scales related to this topic); 7. Pregnant and lactating women; 8. According to the researcher's judgment, the clinical study cannot be completed due to other reasons.

Design outcomes

Primary

MeasureTime frame
CSDH hematoma volume;Recurrence time of CSDH;

Secondary

MeasureTime frame
Karnofsky (KPS) functional status score;NDS (Clinical Neurological Deficiency) Score;Barthel Index (Life Ability Score);MMSE (Cognitive Function) Score;

Countries

China

Contacts

Public ContactXiaoxuan Fan

Affiliated Hospital of Shaanxi University of Chinese Medicine

szfyfxx@163.com+86 139 9101 6360

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026